| Pharmaceutical Companies: Challenges in Developing New Therapeutic Products | February 26, 2003 |
Gordon Ringold
|
Surromed |
Entrepreneurial Thought Leader Lectures |
| Views: 785 |
|
| Video 7 of 14 from this talk |
- 01:59What is an Entrepreneur?
- 01:15Importance of Passion
- 01:37Being an Entrepreneur in Industry vs. Education: Team vs. Individual
- 02:46Types of Company in Biotech
- 03:20History: From Bayer to Affymax
- 02:58Biotech: Collaboration vs. Competition in Developing Affymax
- 01:56Pharmaceutical Companies: Challenges in Developing New Therapeutic Products
- 01:21Funding Challenges in Today's Market
- 01:21History of Maxygen
- 16:12History of Surromed
- 02:00Biggest Pharmaceutical Products in Industry Today
- 01:15How to Operate in a Downturn Economy
- 01:41When and How are Patents Important?
- 04:03Change the Business Plan in Response to a Changing Environment
Description
Ringold talks about how the pharmaceutical industry is built on failure and inefficiency and has a small success rate. This recognition led to Surromed. The low success rate is driving the consolidation of companies, which is giving rise to mega players. Now a blockbuster product has to be a multibillion product. This can only change with a change in the processes it uses. New biotech companies are starving for funding and cash, he notes.
Comments 
Related Videos:
